The United States International Trade Commission (USITC) determined that the U.S. industry was materially injured by reason of imports of methionine from France that the U.S. Department of Commerce (Commerce) has determined were sold in the United States at less than fair value. As a result of the Commission’s affirmative determination, Commerce will issue an antidumping duty order on imports of this product from France.

The Commission also made negative critical circumstances findings with regard to imports of this product from France. As a result, these imports will not be subject to retroactive antidumping duties.

This final determination by the ITC is part of an investigation into methionine dumping in the U.S. In July 2020, Novus International, Inc. filed petitions requesting that the ITC and U.S. Department of Commerce investigate alleged illegal methionine dumping from Spain, France and Japan. Novus believed the U.S. methionine market experienced injury as a result of methionine products from those three countries being sold below market value. The final determination with regards to imports from Spain and Japan is expected in August.

Ed Galo, Novus vice president and chief commercial officer for Americas and EMEA, said that the announcement validates the work his company has done for more than a year to bring these circumstances to light. “Fairtrade practices are essential to the long-term health of any industry. Submitting the antidumping petitions to the ITC and Commerce in July of 2020 was no small effort, and since then we have worked very hard to show the intentional imbalance in the U.S. methionine market. I congratulate the team for their hard work; it’s rewarding to see this positive outcome,” Galo said.